News
After a sluggish 2025, biotech IPOs have roared back to life. Fueled by resilient stock performances and improving market sentiment, the total number of public debuts so far this year has already eclipsed 2025’s total.
FEATURED STORIES
As antibody-drug conjugates advance and move into earlier lines of treatment, drug developers have to build gentler therapies that don’t just extend survival but improve it.
FDA’s rare disease decisions are strongest when the patient community has a voice in advisory committee decisions.
The lineup at the Alzheimer’s Association International Conference will provide critical insight into where the industry is headed with regard to targets being explored to vanquish the elusive neurodegenerative disease.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
Congressional letters sent to the CEOs of Eli Lilly, Pfizer, Merck, BMS and AbbVie this week voicing concerns about the pharmas’ clinical trials in China highlight an ongoing discrepancy in how government and industry think about the rise of the Asian country’s biotech industry.
THE LATEST
Here’s a look at a few of the industry expansions that have been announced so far this month.
Industry watchers question why Elizabeth Holmes has been singled out for failing to deliver what she promised while other tech executives are given a pass.
Intra-Cellular Therapies published its Study 404 Phase III trial of lumateperone as monotherapy for major depressive episodes associated with bipolar I or bipolar II disorder.
Diabetes player Novo Nordisk cut a deal this week, announcing a settlement agreement to put an end to a lawsuit filed in January 2017 by American Depository Receipt investors.
Biohaven Pharma’s latest update on its Phase III clinical trial to use verdiperstat as a potential treatment for multiple system atrophy showed that it did not meet its expected outcomes.
The company aims to treat different forms of mental illness and brain disorders with its pipeline.
With Pfizer expected to submit its COVID-19 vaccine data for children five to 11 years to regulators, a study showed just how damaging the pandemic has been to life expectancy. Here’s a look.
The analysis showed a 52-week glucose remission rate of 65.2% among the 69 patients being followed.
The initiative marks a milestone in the biopharmaceutical industry’s COVID-19 response efforts as it now seeks to protect not just those who had contracted the virus but also those who are around them.
The U.S. Food and Drug Administration is wrapping up the end of September and beginning October with two PDUFA dates. Here’s a look.